


## PHARMACEUTICAL 2023



## Intra-Cellular Therapies Inc. Rank 93 of 446





## PHARMACEUTICAL 2023



## Intra-Cellular Therapies Inc. Rank 93 of 446



The relative strengths and weaknesses of Intra-Cellular Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Intra-Cellular Therapies Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Intra-Cellular Therapies Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 204%, being 161% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	737,957
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	83,236
Liabilities, Non-Current	15,474
Other Assets	14,910
Other Compr. Net Income	-3,826
Other Expenses	20,449
Other Liabilities	0
Other Net Income	7,376
Other Revenues	250,314
Property and Equipment	1,913
Research and Development	134,715
Selling, General and Administrative Expense	358,782

Output Variable	Value in 1000 USD
Assets	754,780
Liabilities	98,710
Expenses	513,946
Revenues	250,314
Stockholders Equity	656,070
Net Income	-256,256
Comprehensive Net Income	-258,169
Economic Capital Ratio	204%

